An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection

Table 2 Health economic outcomes

Outcome	Unadjusted (PAS)			Adjusted (MVAS)
Outcome	Daptomycin (n = 118)	Vancomycin (n = 106)	P value	Rate ratio^b	P value
IRLOS, hours, mean (SD)	91.5 (57.8)	93.2 (60.8)	0.823	1.002 (0.844–1.191)	0.979
Total LOS, hours, mean (SD)	98.5 (77.0)	101.2 (72.1)	0.785	1.018 (0.861–1.204)	0.833
Total inpatient cost, 2012 US$, mean (SD)^a	9641 (6683)	9083 (5855)	0.509	0.940 (0.803–1.101)	0.442

IRLOS infection-related length of stay, LOS length of stay, MVAS multivariate analytic sample, PAS primary analytic sample, SD standard deviation
^aWholesale acquisition cost estimates using “waste” algorithm
^bRate ratio reflects effect of vancomycin relative to daptomycin on outcome of interest. Ratios reported as mean (95 % confidence interval)

ISSN: 1471-2334